Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of HDM2005 combined with standard therapy in diffuse large B-cell lymphoma
CTR20252695Phase 2Active
- Sponsor
- 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HDM2005 in diffuse large B-cell lymphoma (DLBCL), sponsored by 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.). Started Sep 2025; status: active.
02
Drugs
HDM2005
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20252695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252695.